-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Patients with cardiac arrhythmias (atrial fibrillation) have a high risk of thrombotic events in their blood vessels, which can lead to permanent organ damage - such as cerebral infarction - and are prescribed antithrombotic therapy to reduce their occurrence Risk of blood clots
Renal function is known to be associated with the risk of bleeding events, and Kumamoto, Miyazaki, and Tohoku University conducted a post hoc analysis of atrial fibrillation and ischemic events in patients with stable coronary artery disease (AFIRE) using rivaroxaban Group analysis to determine the effect of renal function on the risk of recurrent bleeding events during antithrombotic therapy
In most cases, even after a bleeding event, continuation of antithrombotic therapy is considered better as long as the event is not severe
"It is strongly recommended that patients and physicians have a detailed discussion based on all current scientific evidence on the risks and benefits of antithrombotic therapy," said Dr.
Journal Reference :
Kunihiko Matsui, Satoshi Yasuda, Koichi Kaikita, Masaharu Akao, Junya Ako, Tetsuya Matoba, Masato Nakamura, Katsumi Miyauchi, Nobuhisa Hagiwara, Kazuo Kimura, Atsushi Hirayama, Hisao Ogawa.
